The Exciting Story of OWC Pharmaceutical Research Corp(OTCMKTS:OWCP)


OWC Pharmaceutical Research Corp(OTCMKTS:OWCP) continues to a lot of volatility over its $0.40 base where it has been trading in recent months. OWCP does have a history of big moves running up last year like few stocks ever do running from $0.003 lows to highs of $3.23 a share.

OWCP operates in the red hot Marijuana industry has quickly turned into a multi-billion dollar massive growth market that is sweeping across the Country with many new states having legalized the drug.

OWC Pharmaceutical Research Corp(OTCMKTS:OWCP) through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

OWCP wholly owned subsidiary, One World Cannabis (OWC) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD and migraines. OWC is also developing a unique delivery system for the effective delivery and dosage of medical cannabis.

On September 30 OWCP announced it signed an agreement for $300,000 with Medmar LLC (“Medmar”). According to the terms of the agreement, the funds will be allocated to complete the development of the Company’s proprietary psoriasis cream;

Medmar will have exclusive right to manufacture, produce, publicize, promote and market OWC’s Licensed Products in any state in the U.S; The loan is non-interest bearing and will be repaid from royalties generated by the sale of OWC licensed products.

To Find out the inside Scoop on OWCP Subscribe to Right Now by entering your Email in the box below

Commenting on his investment, Steve Weinstein, CEO of Medmar said, “Medmar has been anxious to advance cannabis as medicine, however US regulation makes it very difficult for companies here to actively pursue any type of development in the sector; fortunately, the environment in Israel is more favorable to the industry.”

In October OWCP announced it has completed the development of a proprietary, cannabinoid-enriched sublingual tablet (the “Tablet”) for the administration of medical cannabis.

The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through oral epithelial tissue.  The Tablet also enables physicians to safely and accurately monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking.

On February 20 OWCP announced the appointment of Dr. Oron Yacoby Zeevias its Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry. She joined Neuroderm , a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders in 2008 as the Vice President of Research and was promoted to the position of VP R&D in 2010. From October 2016 until her recent departure, she served as Chief Scientific Officer. Neuroderm was sold to Mitsubishi Tanabe Pharma for US $1.1 billion in July 2017.

Dr. Yacoby Zeevi is the inventor of over 50 issued patents and pending patents. Her expertise lies in industry-oriented innovation and scientific research, accelerating and orchestrating the evolution of new ideas through R&D proof of concept, intellectual property development, chemistry and manufacturing controls (CMC), early efficacy and safety trials, regulatory affairs and market landscape mapping in fields of unmet medical needs. She earned her Ph.D. in microbiology and immunology from Ben Gurion University in Be’er Sheva, Israel and also holds a degree of Doctor in Veterinary Medicine from the Hebrew University of Jerusalem.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $67 million market valuation OWCP has $2 million cash on the books and rising debt. OWCP is an exciting story developing in small caps; the Company is developing cannabis-based pharmaceuticals and treatments targeting a variety of different medical conditions and disorders including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP has also become an Investors favorite with ready liquidity, big momentum and a breakout chart. We will be updating on OWCP when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with OWCP.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in OWCP either long or short and we have not been compensated for this article.


Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.